Company intelligence / Profile preview

Intima Bioscience

New York City, New York, USAintimabioscience.com ↗

Ownership: Private
Development stage: Phase 1

Overview

Intima Bioscience is conducting Phase 1/2 clinical trials evaluating the safety and efficacy of autologous tumor-infiltrating lymphocytes genetically engineered via CRISPR to knock out the CISH immune checkpoint. Early-stage results are not yet published, but the company is actively enrolling patients with metastatic gastrointestinal cancers.

Therapeutic areas: Oncology
Modalities: Tumor-infiltrating lymphocytes (TILs)Genetically engineered cell therapyCRISPR/Cas9 gene editingmRNA (pipeline includes at least one mRNA program)AAV-based gene therapy (in discovery phase)
Industry: Biotech

Drug pipeline

2 assets

cish inactivated til

1 more asset in the full pipeline.

Request access →

Partnerships

MaxCyte – licensing agreement for Flow Electroporation® technology and ExPERT™ platform [5],[8]

Beyond the preview

Go deeper on Intima Bioscience.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Intima Bioscience.

Explore the full profile